The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-65
SponsorThe First Affiliated Hospital of Soochow University
About this trial
The goal of this observational study is to learn about the effects and safety of Rimegepant in women, especially young and middle-aged women, who take Rimegepant to treat their migraine in the real world. Participants already taking Rimegepant (75mg QOD) as their regular preventive treatment of migraine for 12 weeks will be evaluated as the followings :
1. To evaluate the change from baseline in the mean number of migraine days per month during weeks 1-12 2. To evaluate the number of participants that have least a 50% reduction from baseline in the mean number of migraine days per month during weeks 1-12
Eligibility criteria
Qualifiers
Female participants aged ≥ 18 years-old
Primary diagnosis of migraine according to ICHD-3 3.4 or more migraine days during Observation Period and Screening Visit
Disqualifiers
Patients diagnosed with secondary headaches.
Women who are pregnant or breastfeeding.
Subjects with severe impairments in language, vision, memory, or cognitive function that affect communication and understanding, or those who are unable to complete questionnaires or follow-ups.
Subjects lacking the equipment to complete questionnaires on a digital platform.
Trial design
Treatments tested in this trial
- Rimegepant
Treatment groups
300 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov